Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.
Follow-Up Questions
Qui est le CEO de Better Therapeutics Inc ?
Mr. Craig Jalbert est le President de Better Therapeutics Inc, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action BTTX ?
Le prix actuel de BTTX est de $0.0002, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Better Therapeutics Inc ?
Better Therapeutics Inc appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Better Therapeutics Inc ?
La capitalisation boursière actuelle de Better Therapeutics Inc est de $9972
Est-ce que Better Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Better Therapeutics Inc, y compris 2 achat fort, 5 achat, 1 maintien, 0 vente et 2 vente forte
